New insights in prevention and treatment of sepsis-induced acute kidney injury

Patrick M. Honore1*, Rita Jacobs1, Olivier Joannes-Boyau2, Willem Boer3, Elisabeth De Waele1, Viola Van Gorp1, Herbert D. Spapen1

1Intensive Care Medicine, Intensive Care Dept, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium; 2ICU Consultant, Haut Leveque University Hospital of Bordeaux, University of Bordeaux 2, Pessac, France; 3Department of Anaesthesiology and Critical Care Medicine, Ziekenhuis Oost-Limburg, Genk, Belgium

ABSTRACT

Sepsis-induced acute kidney injury (SAKI) remains an important challenge for intensive care unit clinicians. We reviewed current available evidence regarding prevention and treatment of SAKI thereby incorporating some major recent advances and developments. Prevention includes early and ample administration of “balanced” crystalloid solutions such as Ringer’s lactate. For monitoring of renal function during resuscitation, lactate clearance rate is preferred above S\textsubscript{cv}O\textsubscript{2} or renal Doppler. Aiming at high central venous pressures seems to be deleterious in light of the novel “kidney afterload” concept. Noradrenaline is the vasopressor of choice for preventing SAKI. Intra-abdominal hypertension, a potent trigger of acute kidney injury in postoperative and trauma patients, should not be neglected in sepsis. Renal replacement therapy (RRT) must be started early in fluid-overloaded patients refractory to diuretics. Continuous RRT (CRRT) is the preferred modality in hemodynamically unstable SAKI but its use in more stable SAKI is increasing. In the absence of hypervolemia, diuretics should be avoided. Antimicrobial dosing during CRRT needs to be thoroughly reconsidered to assure adequate infection control.

Key words: acute kidney injury, bedside management, medical therapies, prevention, sepsis

PREVENTION OF SEPSIS-INDUCED ACUTE KIDNEY INJURY (AKI)

Fluid resuscitation

Aim

The old “credo” stating that fluid harms the lung but benefits the kidney should be revised.[1] Liberal fluid administration is of key importance to optimize systemic hemodynamics in patients with sepsis-induced acute kidney injury (SAKI). Yet, ongoing controversy exists about efficacy, nature, extent and duration of fluid resuscitation in septic shock.[2] In fact, intensive care unit physicians are faced with a “double-edged” fluid dilemma. Volume resuscitation is indeed essential to restore and maintain cardiac output and oxygen delivery. Sustained or unrestricted infusion of fluids, however, will cause tissue edema which may significantly contribute to organ dysfunction. On the other hand, too rapid or excessive fluid removal with diuretics or extracorporeal techniques might cause severe hypovolemia and recurrent renal injury. An optimal stepwise approach is to guarantee a smooth transition from initial unrestricted fluid resuscitation (positive fluid balance), managing a state of equilibrium (steady fluid balance) and finally assuring an appropriate rate of fluid removal (negative fluid balance).[3] This process is kept on track by meticulous and serial assessments of fluid handling aiming at well-defined cardiovascular and renal targets. Patients developing SAKI are evidently more susceptible to fluid accumulation and thus particularly prone to its harmful consequences.[4] Early use of
renal replacement therapy (RRT) in this population will offer the best possible outcome.

Type of fluids
Hypotension and hypovolemia during sepsis may cause or worsen AKI. Increasing evidence suggests that isotonic crystalloid solutions should be used instead of colloids for initial intravascular volume expansion in septic patients at risk for AKI.[10] Timing and amount of volume to prevent SAKI (and other organ damage) remain a matter of debate. Although early aggressive fluid resuscitation is considered to be beneficial,[7] observational studies in critically ill patients with SAKI have linked fluid overload to increased mortality and reduced kidney recovery.[8] The substantial risk for induction of osmotic nephrosis (by pinocytosis in the renal tubules) strongly pleads against the use of hydroxyethyl starch and dextran solutions.[9] Balanced crystalloid perfusions (e.g., Ringer’s lactate) may be preferred above isotonic salt solutions.[10] The latter contain a high chloride load which may be detrimental for the kidney.[11]

Albumin
It is a common belief that albumin 5% or 20% solutions, through a hyperoncotic effect, will force excess water back from the tissues into the endovascular space.[12] Surprisingly, this has never been evidenced! On the contrary, it was recently shown that albumin infusion rather promotes extracellular fluid overload without improving hypovolemia.[13] Accordingly, more data are needed before albumin infusion can be recommended for prevention of SAKI.

Early use of continuous RRT (CRRT)
Fluid overload definitely increases kidney edema and enhances severity and irreversibility of SAKI.[3,14] Therefore, timely use of CRRT in cases of fluid overload that are poorly responding or refractory to diuretics might be a reasonable approach to attenuate or control SAKI.[14] CRRT reduced mortality in acutely ill fluid-overloaded children.[15]

Monitoring
Renal doppler
The kidneys receive approximately 25% of total blood flow of which they use less than half mainly because of intricate intrarenal shunting.[16] Therefore, monitoring limited to global evaluation of renal blood flow tells very little about the adequacy of oxygen supply to the kidneys.[17] As a consequence, renal Doppler is not a reliable tool to assess oxygen supply and its potential response to fluid loading.[17] Future research should focus on the renal microcirculation.

Central venous oxygen saturation (SvO₂) and lactate clearance rate
It has been suggested that SvO₂ values exceeding 70% are needed to prevent AKI. Recent studies, however, did not find any correlation between restoration of systemic hemodynamics or increasing oxygen supply and occurrence of AKI.[38] Kidney function is less dependent on enhanced oxygen delivery but more sensible to mean arterial perfusion pressure. This explains why noradrenaline better preserves kidney function than dobutamine[39] and lactate clearance rate more adequately mirrors kidney perfusion than SvO₂.[20]

Central venous pressure (CVP) and the “afterload” of the kidney
For decades, clinicians have thought that a high filling pressure was imperative to attenuate the risk for AKI.[18,21] Indeed, by analogy with the heart and starling curve, we believe that only preload was of importance for preserving the kidney by increasing blood volume and flow to the kidney. In the recent years, again by analogy with the heart physiology, it was shown that a certain level of CVP was indeed beneficial for the kidney but could also be detrimental by increasing venous congestion and blocking venous return of the kidney. Venous return has a major impact on kidney function. At this was happening after the kidney, it was named “afterload” of the kidney again by analogy with the heart physiology. Chinese investigators recently demonstrated the negative impact of high CVP on the kidney function. In fact, they showed an increased incidence of AKI at higher levels of CVP.[21] A possible explanation of this controversial finding could be unexpected changes in kidney afterload resulting in deleterious venous congestion.[18] In view of these findings, a CVP of 8 to 10 mmHg may be ideal for adequate kidney perfusion while a CVP above 12 mmHg could be harmful.[18,21,22]

Differentiating transient (functional) from structural SAKI
Low fractional excretions of sodium (FE Na) and urea (FE Urea) are highly prevalent during the initial phase of sepsis. Oliguria is an earlier sign of impending SAKI than the increase in serum creatinine. A combination of a high FE Na and a low FE Urea value is associated with intrinsic SAKI whereas high values for both FE Na and FE Urea are strongly predictive for transient or functional SAKI.[24] Nevertheless, these biochemical parameters do not perform as well as specific biomarkers of SAKI.[28] Among the most recent biomarker assays, the neutrophil gelatinase associated lipocalin and the nephrocheck test are promising tools for bedside differentiation between transient and structural SAKI.[25,26] However, due to their limited availability, these biomarkers cannot be recommended for guiding therapy.
Transfusion policy
From a physiological viewpoint, a hematocrit level of 30% was considered to be an optimal target within the prevention measures for SAKI.[27] A recent retrospective study, however, showed that red blood cell transfusion in non-bleeding critically ill patients with moderate anemia and without shock was associated with higher nosocomial infection rates, more AKI and increased mortality.[28] This apparent “transfusion-related AKI” could be coined by the acronym “TRAKI” in analogy to the recognized “TRALI” which stands for “transfusion related acute lung injury”. [29]
Regarding prevention of SAKI, a hematocrit level of 25% may be a more realistic target.[28] Interestingly, the introduction of citrate as an anticoagulant during CRRT has resulted in significantly lower transfusion needs. A potential beneficial role of citrate on preservation and/or recovery of SAKI has been suggested[30] but needs confirmation.

Vasopressive and inotropic support
As discussed earlier, renal flow and oxygen supply have been wrongly considered to be determining players in the pathophysiology of SAKI.[18,21] SAKI was thought to result from ischemia due to a reduced blood flow[30] and therapy aimed to increase filling pressures (i.e., fluid administration) and cardiac output (i.e., inotropic support). This concept was challenged by Di Giantomasso et al. who demonstrated in an experimental hyperdynamic septic shock model that noradrenaline (i.e., vasopression) significantly increased global and medullary renal blood flow and restored renal vascular tone toward normal.[32] Vasopressin does not offer the advantage over noradrenaline. The vasopressin and septic shock trial did not show any difference in incidence of AKI or need for RRT with the use of vasopressin.[33]

Intra-abdominal hypertension
Post-chirurgical incidence
Intra-abdominal hypertension (IAH) and its most dreaded presentation, the abdominal compartment syndrome (ACS), are frequently associated with AKI in surgical and traumatic patients. Because signs and symptoms are non-specific and laboratory and imaging studies often remain inconclusive, the diagnosis of AKI as a manifestation of IAH requires a high index of clinical suspicion. Early recognition and treatment improve clinical outcome.[34] IAH has also been described in up to one-third of cardiac surgery patients where it was found to be strongly associated with higher baseline intra-abdominal pressure (IAP), increased CVP, positive fluid balance, extracorporeal circulation, use of vasoactive drugs and AKI. Determinants of IAH therefore need accurate assessment before and after surgery. Patients presenting any known risk factor must be closely monitored during the perioperative period. In this context, the baseline IAP may be a valuable early warning parameter for IAH.[34]

Incidence during SAKI and medical conditions
Once considered mostly a postsurgical condition, IAH and ACS are now thought to increase morbidity and mortality in many patients receiving medical intensive care. Factors predisposing to IAH/ACS include sepsis, large volume fluid resuscitation, polytransfusion, mechanical ventilation with high intrathoracic pressure and acidosis, among others. Transudation of bladder pressure is the gold standard for measuring IAP and several nonsurgical methods can help reduce IAP. The role of RRT for volume management is not well-defined but may be beneficial in some cases. As septic patients mostly require substantially larger amounts of fluids, they are more prone to develop IAH.[34,35] Consequently, any impact of IAH on development and progression of SAKI must be timely considered and anticipated. It is upmost importance to detect early on IAH in post cardiac surgery as they will be more prone to develop very quickly IAH by gathering both group risk factors. Lastly, the role of RRT for volume management may be beneficial in some cases[36]

TREATMENT OF SEPSIS-INDUCED AKI
Timing of CRRT
CRRT should be initiated upfront when fluid overload does insufficiently respond or remains refractory to a diuretic challenge.[3,14,15] In established SAKI, the recently published IVOIRE study[30] suggested to start CRRT at risk, injury, failure, loss, end injury level. Starting at this stage indeed correlated with a very low mortality at 90 days.[36] More data are needed before this approach can be recommended.

Renal replacement modalities
A study by Prowle and Bellomo et al. recently demonstrated that hemodynamically unstable patients with SAKI treated with CRRT remained significantly less dialysis-dependent (5% vs. 25%) than those receiving IHD.[37] Therefore, CRRT is recommended as first-line therapy in this population. A recent meta-analysis suggested superiority of CRRT to IHD in terms of renal recovery in patients without cardiovascular instability.[38] A prospective randomized study is needed to confirm this observation. High-volume hemofiltration has no place in the treatment of SAKI[36,39] now-a-days. In current practice a dialysis dose of 35 ml/kg/h is prescribed to ascertain delivery of at least 25 mL/kg/h.

Role of diuretics
The use of diuretics to provoke or increase urine production in the absence of hypervolemia is associated with increased mortality[40] and should be discouraged. A furosemide stress test has been proposed for early
assessment of tubular function. The test showed robust predictive capacity for identifying patients at risk for severe and progressive AKI but needs further validation.\textsuperscript{[61]} No comparable test predicts renal recovery.

**Antimicrobial dosing during CRRT**

The use of CRRT significantly influences the pharmacokinetic and–dynamic behavior of most antimicrobial agents. This is insufficiently anticipated by currently recommended dosing guidelines. Patients are particularly at risk for underdosing, which may cause treatment failure and enhanced resistance. An in-depth discussion of this topic is beyond the scope of this article.

As you can see in Table 1, dose adaptations for some major antibiotic and antifungal drugs during CRRT are proposed.

**CONCLUSIONS**

Prevention of SAKI starts with early and adequate fluid resuscitation. Balanced crystalloid solutions with lower chloride load (e.g., Ringer's lactate) are preferred. Synthetic colloids should be abandoned. A lactate clearance test is a better tool for monitoring kidney perfusion than $\text{S}_\text{O}_2$ or renal Doppler. In light of the novel “kidney afterload” concept, a high filling pressure should be avoided. Noradrenaline is the vasopressor of choice for preventing SAKI. IAH is a potential, yet often overlooked, trigger of SAKI. Early initiation of RRT is recommended when fluid overload is refractory to diuretics. CRRT is the mobility of choice in hemodynamically unstable SAKI but may also offer better outcome than IHD in stable SAKI. Except for life-threatening hypervolemia, diuretics have no place in the prevention or treatment of SAKI. Antimicrobial therapy requires special attention and adaptation during CRRT.

**REFERENCES**


---

Table 1: Recommendations for antimicrobial dosage during continuous renal replacement therapy

<table>
<thead>
<tr>
<th>Antibiotic/Antifungal</th>
<th>Loading dose</th>
<th>Maintenance dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amikacin</td>
<td>30-35 mg/kg</td>
<td>TDM</td>
</tr>
<tr>
<td>Meropenem</td>
<td>2 g</td>
<td>2 g over 3 h tid</td>
</tr>
<tr>
<td>Piperacillin-tazobactam</td>
<td>4 g/0.5 g</td>
<td>16 g/2 g (Cl)</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>35 mg/kg</td>
<td>30-35 mg/kg</td>
</tr>
<tr>
<td></td>
<td>over 4 h</td>
<td>(TDM = 25-30 mg/L)</td>
</tr>
<tr>
<td>Teicoplanin</td>
<td>3 x 15 mg/kg</td>
<td>600 mg od</td>
</tr>
<tr>
<td></td>
<td>every 12 h</td>
<td></td>
</tr>
<tr>
<td>Linezolid</td>
<td>600 mg mg</td>
<td></td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>800 mg</td>
<td>400 mg tid</td>
</tr>
<tr>
<td>Ticarcillin</td>
<td>150 mg</td>
<td>100 mg bid</td>
</tr>
<tr>
<td>Colistin</td>
<td>9 MIU</td>
<td>4, 5 MIU tid</td>
</tr>
<tr>
<td>Voriconazole</td>
<td>8 mg/kg bid</td>
<td>6 mg/kg bid</td>
</tr>
<tr>
<td>Fluconazole</td>
<td>600 mg bid</td>
<td></td>
</tr>
<tr>
<td>Cefepime</td>
<td>2 g tid</td>
<td></td>
</tr>
<tr>
<td>Gentamicin</td>
<td>7 mg/kg od</td>
<td></td>
</tr>
<tr>
<td>Bacitracin</td>
<td>1200 mg/240 mg</td>
<td>800 mg/160 mg (amp)</td>
</tr>
<tr>
<td></td>
<td>(3 amp)</td>
<td>(2 amp) tid</td>
</tr>
</tbody>
</table>


Source of Support: Nil, Conflict of Interest: None declared